A potential link between AQP3 and SLC14A1 gene expression level and clinical parameters of maintenance hemodialysis patients

Table 6 Correlations between UT-B (SLC14A1) gene expression and clinical data with subdivision according to end-stage kidney disease causes

	GN		AH		DM		Other
	R	P value	R	P value	R	P value	R	P value
Age, years	-0.21	0.34	0.48	0.06	0.02	0.93	0.14	0.62
Urea before hemodialysis, mg/dL	0.30	0.18	-0.43	0.09	0.21	0.35	0.05	0.86
Urea after hemodialysis, mg/dL	0.11	0.64	-0.20	0.46	0.16	0.47	-0.10	0.72
Urea reduction ratio (URR), %	0.23	0.30	-0.26	0.34	0.07	0.77	0.33	0.21
Hb, g/dL	0.17	0.45	-0.34	0.19	0.10	0.65	0.08	0.78
EPO ratio, IU/kg of dry body mass	-0.12	0.61	-0.30	0.26	-0.13	0.56	0.36	0.16
IWG, %	0.47	0.03	-0.28	0.29	0.40	0.06	-0.10	0.71
Hemodialysis session time, min	-0.13	0.57	0.37	0.16	0.23	0.31	0.01	0.96
UF ratio—IWG/dialyser, kg/dialyser m²/h	-0.48	0.02	0.64	0.008	0.08	0.72	-0.18	0.49
Hemodialysis vintage, months	< 0.01	0.99	-0.66	0.005	-0.19	0.40	0.23	0.39
Residual kidney function, mL/24 h	0.03	0.89	0.14	0.60	-0.07	0.76	0.39	0.14

Abbreviations: DM Diabetes mellitus, EPO Erythropoietin, GN Primary glomerulonephritis, AH Arterial hypertension, IWG Interdialytic weight gain, UF Ultrafiltration

ISSN: 1471-2369